UK Biobank (core renewal)
Lead Research Organisation:
UK Biobank
Department Name: UNLISTED
Abstract
UK Biobank is supported by The Wellcome Trust, The National Institute of Health Research, The Medical Research Council, The British Heart Foundation and Cancer Research UK. The figures presented on this record represent the Medical Research Council funding contribution only with some additional UKRI Infrastructure funds in addition.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
Technical Summary
The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. There are now sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
Organisations
People |
ORCID iD |
Rory Collins (Principal Investigator) |
Publications
Petermann-Rocha F
(2021)
The joint association of sarcopenia and frailty with incidence and mortality health outcomes: A prospective study.
in Clinical nutrition (Edinburgh, Scotland)
Petermann-Rocha F
(2020)
Biomarkers Profile of People With Sarcopenia: A Cross-sectional Analysis From UK Biobank.
in Journal of the American Medical Directors Association
Petermann-Rocha F
(2021)
Dose-response association between device-measured physical activity and incident dementia: a prospective study from UK Biobank.
in BMC medicine
Petermann-Rocha F
(2023)
Do all vegetarians have a lower cardiovascular risk? A prospective study.
in Clinical nutrition (Edinburgh, Scotland)
Petermann-Rocha F
(2023)
An Opportunity for Prevention: Associations Between the Life's Essential 8 Score and Cardiovascular Incidence Using Prospective Data from UK Biobank.
in Current problems in cardiology
Petermann-Rocha F
(2022)
Reply to: "Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK Biobank participants".
in Journal of hepatology
Petermann-Rocha F
(2020)
Comparison of two different frailty measurements and risk of hospitalisation or death from COVID-19: findings from UK Biobank.
in BMC medicine
Petermann-Rocha F
(2022)
Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK Biobank participants.
in Journal of hepatology
Petermann-Rocha F
(2021)
Vegetarians, fish, poultry, and meat-eaters: who has higher risk of cardiovascular disease incidence and mortality? A prospective study from UK Biobank.
in European heart journal
Petermann-Rocha F
(2022)
Frailty, sarcopenia, cachexia and malnutrition as comorbid conditions and their associations with mortality: a prospective study from UK Biobank.
in Journal of public health (Oxford, England)
Petermann-Rocha F
(2021)
Nonlinear Associations Between Cumulative Dietary Risk Factors and Cardiovascular Diseases, Cancer, and All-Cause Mortality: A Prospective Cohort Study From UK Biobank.
in Mayo Clinic proceedings
Petermann-Rocha F
(2020)
Sarcopenic obesity and its association with respiratory disease incidence and mortality.
in Clinical nutrition (Edinburgh, Scotland)
Peters EM
(2018)
Neuroticism and suicide in a general population cohort: results from the UK Biobank Project.
in BJPsych open
Peters SA
(2018)
Women's reproductive factors and incident cardiovascular disease in the UK Biobank.
in Heart (British Cardiac Society)
Peters SAE
(2021)
Obesity as a risk factor for COVID-19 mortality in women and men in the UK biobank: Comparisons with influenza/pneumonia and coronary heart disease.
in Diabetes, obesity & metabolism
Peters SAE
(2018)
Sex Differences in the Association Between Measures of General and Central Adiposity and the Risk of Myocardial Infarction: Results From the UK Biobank.
in Journal of the American Heart Association
Peters SAE
(2020)
Sex differences in the association between major risk factors and the risk of stroke in the UK Biobank cohort study.
in Neurology
Peters SAE
(2021)
Oestradiol and the risk of myocardial infarction in women: a cohort study of UK Biobank participants.
in International journal of epidemiology
Peters TM
(2021)
Sex Differences in the Risk of Coronary Heart Disease Associated With Type 2 Diabetes: A Mendelian Randomization Analysis.
in Diabetes care
Petrick JL
(2020)
Exogenous hormone use, reproductive factors and risk of intrahepatic cholangiocarcinoma among women: results from cohort studies in the Liver Cancer Pooling Project and the UK Biobank.
in British journal of cancer
Petzold A
(2021)
Retinal asymmetry in multiple sclerosis.
in Brain : a journal of neurology
Pham D
(2022)
Assessing polygenic risk score models for applications in populations with under-represented genomics data: an example of Vietnam
in Briefings in Bioinformatics
Pham K
(2022)
High coffee consumption, brain volume and risk of dementia and stroke.
in Nutritional neuroscience
Pieri K
(2023)
Polygenic risk in Type III hyperlipidaemia and risk of cardiovascular disease: An epidemiological study in UK Biobank and Oxford Biobank
in International Journal of Cardiology
Piernas C
(2021)
Describing a new food group classification system for UK biobank: analysis of food groups and sources of macro- and micronutrients in 208,200 participants.
in European journal of nutrition
Piernas C
(2022)
Dietary patterns derived by reduced rank regression and non-communicable disease risk.
in The Proceedings of the Nutrition Society
Pierson E
(2019)
Inferring Multidimensional Rates of Aging from Cross-Sectional Data.
in Proceedings of machine learning research
Pierzycki RH
(2021)
Associations Between Hearing Health and Well-Being in Unilateral Hearing Impairment.
in Ear and hearing
Pierzycki RH
(2021)
Insomnia, Anxiety and Depression in Adult Cochlear Implant Users With Tinnitus.
in Ear and hearing
Piga NN
(2022)
Genetic insights into smoking behaviours in 10,558 men of African ancestry from continental Africa and the UK.
in Scientific reports
Pigeyre M
(2020)
ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study.
in Diabetes care
Pillalamarri V
(2023)
Whole-exome sequencing in 415,422 individuals identifies rare variants associated with mitochondrial DNA copy number
in Human Genetics and Genomics Advances
Pillay P
(2023)
Independent Relevance of Different Measures of Adiposity for Carotid Intima-Media Thickness in 40 000 Adults in UK Biobank.
in Journal of the American Heart Association
Pillay P
(2022)
Adiposity, Body Fat Distribution, and Risk of Major Stroke Types Among Adults in the United Kingdom.
in JAMA network open
Pilling LC
(2019)
Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK Biobank.
in BMJ (Clinical research ed.)
Pilling LC
(2018)
Red cell distribution width and common disease onsets in 240,477 healthy volunteers followed for up to 9 years.
in PloS one
Pilling LC
(2022)
Genetic modifiers of penetrance to liver endpoints in HFE hemochromatosis: Associations in a large community cohort.
in Hepatology (Baltimore, Md.)
Pilling LC
(2021)
Low Vitamin D Levels and Risk of Incident Delirium in 351,000 Older UK Biobank Participants.
in Journal of the American Geriatrics Society
Pillinger T
(2023)
Effect of polygenic risk for schizophrenia on cardiac structure and function: a UK Biobank observational study.
in The lancet. Psychiatry
Pinaya WHL
(2021)
Using normative modelling to detect disease progression in mild cognitive impairment and Alzheimer's disease in a cross-sectional multi-cohort study.
in Scientific reports
Pinaya WHL
(2022)
Unsupervised brain imaging 3D anomaly detection and segmentation with transformers.
in Medical image analysis
Pinese M
(2020)
The Medical Genome Reference Bank contains whole genome and phenotype data of 2570 healthy elderly.
in Nature communications
Description | Impact of clinically silent atrial fibrillation on cerebrovascular disease and cognitive decline in the UK Biobank Imaging Cohort |
Amount | £2,474,260 (GBP) |
Funding ID | RG/18/6/33576 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2019 |
End | 06/2024 |
Description | UK Biobank - The Repeat Imaging Project |
Amount | £2,500,000 (GBP) |
Funding ID | R39738/CN039 |
Organisation | MRC Dementias Platform UK |
Sector | Academic/University |
Country | United Kingdom |
Start | 04/2019 |
End | 01/2023 |
Description | UK Biobank - Whole genome sequencing of 50,000 UKB participants |
Amount | £30,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2020 |
Description | UK Biobank- Expansion of the UKB imaging to a 4th centre and repeat imaging assessment of 10,000 participants |
Amount | £8,500,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 12/2022 |
Description | UK Biobank Scientific Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London |
Year(s) Of Engagement Activity | 2018 |
Description | UK Biobank participant imaging event |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UK Biobank for participants of the imaging work |
Year(s) Of Engagement Activity | 2021 |
Description | UKBiobank participant events - 2014 - 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2020 over 4,000 participants have taken part in events in Edinburgh (4), Manchester (4), Nottingham, Leeds, Cardiff (2), Newcastle (5), Glasgow (2), Bristol (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing) |
Year(s) Of Engagement Activity | 2014,2015,2016,2017,2018,2019 |
URL | http://www.ukbiobank.ac.uk |